A clinical trial assessing HBM1022
Latest Information Update: 13 Feb 2023
At a glance
- Drugs HBM 1022 (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 13 Feb 2023 New trial record
- 07 Feb 2023 According to Harbour BioMed media release, the company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration of the United States (FDA) to initiate this trial